Introduction
In a groundbreaking collaboration, OGT, a trailblazer in genomic research solutions, and Qiagen Digital Insights (QDI), a leading provider of genomic analysis tools, have joined forces. This partnership marks a significant milestone in the field of bioinformatics by integrating QDI’s cutting-edge tertiary analysis solution, QCI Interpret, with OGT’s SureSeq NGS panels. This integration aims to enhance bioinformatics capabilities, providing users with a streamlined and efficient sample-to-report workflow.
Unveiling QCI Interpret
QCI Interpret, renowned for its AI-powered variant interpretation and clinical reporting capabilities, offers expert-curated classifications, oncologist-reviewed summaries, and transparent evidence links. By leveraging the world’s largest expert-curated knowledge base of genomic content, QCI Interpret combines the precision of expert curation with the speed and scalability of AI-powered automation. This amalgamation empowers labs to deliver high-confidence variant interpretations and reports, ensuring accurate and efficient genomic insights for SureSeq NGS panel users.
SureSeq NGS Panels: Setting a New Standard
OGT’s SureSeq NGS panels are designed to provide superior hybridization-based detection capabilities, enabling clinical research labs to achieve comprehensive genomic profiling with ease. By integrating Qiagen’s proprietary software, labs can now access an end-to-end workflow that ensures faster, more informed, and confident insights. This collaboration sets a new standard in genomic analysis, offering unparalleled accuracy and consistency to users.
The Power of Collaboration
Gareth Thomson, Executive Vice President of Commercial Operations at OGT, expressed enthusiasm about the partnership, highlighting its significance in enhancing customer confidence in variant classification. The collaboration with QDI underscores OGT’s commitment to delivering impactful oncology insights, providing customers with access to the world’s largest knowledge base for genomic interpretation.
Nitin Sood, Senior Vice President and Head of Life Sciences at Qiagen, emphasized the partnership’s global impact, particularly in supporting labs worldwide. By leveraging QDI’s expertise in variant interpretation, labs can scale confidently, reduce turnaround times, and improve outcomes for patients. This collaboration exemplifies a shared mission to advance healthcare diagnostics and testing.
Sysmex: Driving Innovation in Diagnostics
As part of the Sysmex Group, a leading haematology diagnostics provider, OGT’s partnership with Qiagen further accelerates advancements in diagnostics and testing. By bringing together expertise from both entities, labs and researchers are empowered to shape the future of healthcare through innovative solutions and cutting-edge technologies.
OGT: A Global Leader in Genomic Solutions
OGT, a Sysmex Group company, is renowned for its clinical and diagnostic genomic solutions, including the CytoCell, CytoSure, and SureSeq product ranges. Designed by scientists for scientists, OGT’s products cater to a wide range of research and diagnostic needs, providing unparalleled accuracy and reliability in genomic analysis.
Qiagen Digital Insights: Pioneering Genomic Analysis
Qiagen Digital Insights (QDI) stands at the forefront of genomic and clinical knowledge, offering analysis, interpretation tools, and services for scientists and clinicians worldwide. With a focus on precision medicine and cutting-edge solutions, QDI continues to drive innovation in genomic analysis and interpretation.
Additional Thoughts
The partnership between OGT and QDI represents a significant leap forward in the field of genomic analysis, offering users a comprehensive and seamless workflow for genomic insights. By combining OGT’s expertise in genomic solutions with QDI’s advanced bioinformatics capabilities, labs and researchers can now access a powerful toolkit that streamlines variant interpretation and reporting. This collaboration not only enhances the efficiency and accuracy of genomic analysis but also paves the way for future innovations in precision medicine.
Tags: bioinformatics, automation
Read more on pharmabiz.com